Astria Therapeutics (ATXS) announced the initiation of the Phase 3 ORBIT-EXPANSE long-term trial of navenibart in people living with hereditary angioedema.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- Astria Therapeutics begins enrollment in EU for ALPHA-ORBIT trial
- Astria Therapeutics price target raised to $26 from $25 at Evercore ISI
- Buy Rating for Astria Therapeutics: Promising Clinical Data and Market Advantages of STAR-0310
- Promising Potential of Astria Therapeutics’ STAR-0310 in Atopic Dermatitis: Analyst Recommends Buy
- Astria Therapeutics price target raised to $20 from $16 at H.C. Wainwright